Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models

Anat Frydman-Marom, Aviad Levin, Dorit Farfara, Tali Benromano, Roni Scherzer-Attali, Sivan Peled, Robert Vassar, Daniel Segal, Ehud Gazit*, Dan Frenkel, Michael Ovadia

*Corresponding author for this work

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

An increasing body of evidence indicates that accumulation of soluble oligomeric assemblies of β-amyloid polypeptide (Aβ) play a key role in Alzheimer's disease (AD) pathology. Specifically, 56 kDa oligomeric species were shown to be correlated with impaired cognitive function in AD model mice. Several reports have documented the inhibition of Aβ plaque formation by compounds from natural sources. Yet, evidence for the ability of common edible elements to modulate Aβ oligomerization remains an unmet challenge. Here we identify a natural substance, based on cinnamon extract (CEppt), which markedly inhibits the formation of toxic Aβ oligomers and prevents the toxicity of Aβ on neuronal PC12 cells. When administered to an AD fly model, CEppt rectified their reduced longevity, fully recovered their locomotion defects and totally abolished tetrameric species of Aβ in their brain. Furthermore, oral administration of CEppt to an aggressive AD transgenic mice model led to marked decrease in 56 kDa Aβ oligomers, reduction of plaques and improvement in cognitive behavior. Our results present a novel prophylactic approach for inhibition of toxic oligomeric Aβ species formation in AD through the utilization of a compound that is currently in use in human diet.

Original languageEnglish (US)
Article numbere16564
JournalPLoS One
Volume6
Issue number1
DOIs
StatePublished - Feb 7 2011

Fingerprint

Cinnamomum zeylanicum
Oligomerization
cinnamon
disease models
amyloid
Alzheimer disease
Amyloid
Alzheimer Disease
Animals
Animal Models
animal models
extracts
Poisons
Oligomers
Aptitude
PC12 Cells
Pathology
Locomotion
Nutrition
cognition

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Frydman-Marom, A., Levin, A., Farfara, D., Benromano, T., Scherzer-Attali, R., Peled, S., ... Ovadia, M. (2011). Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. PLoS One, 6(1), [e16564]. https://doi.org/10.1371/journal.pone.0016564
Frydman-Marom, Anat ; Levin, Aviad ; Farfara, Dorit ; Benromano, Tali ; Scherzer-Attali, Roni ; Peled, Sivan ; Vassar, Robert ; Segal, Daniel ; Gazit, Ehud ; Frenkel, Dan ; Ovadia, Michael. / Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. In: PLoS One. 2011 ; Vol. 6, No. 1.
@article{55bd7f4d4b1046fd98183a79dc8085c5,
title = "Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models",
abstract = "An increasing body of evidence indicates that accumulation of soluble oligomeric assemblies of β-amyloid polypeptide (Aβ) play a key role in Alzheimer's disease (AD) pathology. Specifically, 56 kDa oligomeric species were shown to be correlated with impaired cognitive function in AD model mice. Several reports have documented the inhibition of Aβ plaque formation by compounds from natural sources. Yet, evidence for the ability of common edible elements to modulate Aβ oligomerization remains an unmet challenge. Here we identify a natural substance, based on cinnamon extract (CEppt), which markedly inhibits the formation of toxic Aβ oligomers and prevents the toxicity of Aβ on neuronal PC12 cells. When administered to an AD fly model, CEppt rectified their reduced longevity, fully recovered their locomotion defects and totally abolished tetrameric species of Aβ in their brain. Furthermore, oral administration of CEppt to an aggressive AD transgenic mice model led to marked decrease in 56 kDa Aβ oligomers, reduction of plaques and improvement in cognitive behavior. Our results present a novel prophylactic approach for inhibition of toxic oligomeric Aβ species formation in AD through the utilization of a compound that is currently in use in human diet.",
author = "Anat Frydman-Marom and Aviad Levin and Dorit Farfara and Tali Benromano and Roni Scherzer-Attali and Sivan Peled and Robert Vassar and Daniel Segal and Ehud Gazit and Dan Frenkel and Michael Ovadia",
year = "2011",
month = "2",
day = "7",
doi = "10.1371/journal.pone.0016564",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

Frydman-Marom, A, Levin, A, Farfara, D, Benromano, T, Scherzer-Attali, R, Peled, S, Vassar, R, Segal, D, Gazit, E, Frenkel, D & Ovadia, M 2011, 'Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models', PLoS One, vol. 6, no. 1, e16564. https://doi.org/10.1371/journal.pone.0016564

Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. / Frydman-Marom, Anat; Levin, Aviad; Farfara, Dorit; Benromano, Tali; Scherzer-Attali, Roni; Peled, Sivan; Vassar, Robert; Segal, Daniel; Gazit, Ehud; Frenkel, Dan; Ovadia, Michael.

In: PLoS One, Vol. 6, No. 1, e16564, 07.02.2011.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models

AU - Frydman-Marom, Anat

AU - Levin, Aviad

AU - Farfara, Dorit

AU - Benromano, Tali

AU - Scherzer-Attali, Roni

AU - Peled, Sivan

AU - Vassar, Robert

AU - Segal, Daniel

AU - Gazit, Ehud

AU - Frenkel, Dan

AU - Ovadia, Michael

PY - 2011/2/7

Y1 - 2011/2/7

N2 - An increasing body of evidence indicates that accumulation of soluble oligomeric assemblies of β-amyloid polypeptide (Aβ) play a key role in Alzheimer's disease (AD) pathology. Specifically, 56 kDa oligomeric species were shown to be correlated with impaired cognitive function in AD model mice. Several reports have documented the inhibition of Aβ plaque formation by compounds from natural sources. Yet, evidence for the ability of common edible elements to modulate Aβ oligomerization remains an unmet challenge. Here we identify a natural substance, based on cinnamon extract (CEppt), which markedly inhibits the formation of toxic Aβ oligomers and prevents the toxicity of Aβ on neuronal PC12 cells. When administered to an AD fly model, CEppt rectified their reduced longevity, fully recovered their locomotion defects and totally abolished tetrameric species of Aβ in their brain. Furthermore, oral administration of CEppt to an aggressive AD transgenic mice model led to marked decrease in 56 kDa Aβ oligomers, reduction of plaques and improvement in cognitive behavior. Our results present a novel prophylactic approach for inhibition of toxic oligomeric Aβ species formation in AD through the utilization of a compound that is currently in use in human diet.

AB - An increasing body of evidence indicates that accumulation of soluble oligomeric assemblies of β-amyloid polypeptide (Aβ) play a key role in Alzheimer's disease (AD) pathology. Specifically, 56 kDa oligomeric species were shown to be correlated with impaired cognitive function in AD model mice. Several reports have documented the inhibition of Aβ plaque formation by compounds from natural sources. Yet, evidence for the ability of common edible elements to modulate Aβ oligomerization remains an unmet challenge. Here we identify a natural substance, based on cinnamon extract (CEppt), which markedly inhibits the formation of toxic Aβ oligomers and prevents the toxicity of Aβ on neuronal PC12 cells. When administered to an AD fly model, CEppt rectified their reduced longevity, fully recovered their locomotion defects and totally abolished tetrameric species of Aβ in their brain. Furthermore, oral administration of CEppt to an aggressive AD transgenic mice model led to marked decrease in 56 kDa Aβ oligomers, reduction of plaques and improvement in cognitive behavior. Our results present a novel prophylactic approach for inhibition of toxic oligomeric Aβ species formation in AD through the utilization of a compound that is currently in use in human diet.

UR - http://www.scopus.com/inward/record.url?scp=79551537131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551537131&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0016564

DO - 10.1371/journal.pone.0016564

M3 - Article

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e16564

ER -